Human Rabies Immunoglobulin Bio Products Laboratory (Human Rabies Immunoglobulin)

Human Rabies Immunoglobulin is indicated for the passive immunization of individuals who have potentially been exposed to the rabies virus. It is used as part of a comprehensive post‑exposure prophylaxis regimen together with rabies vaccine.

• Immediate neutralization of rabies virus at the wound site.
• Supplementation of active immunity when vaccine response may be delayed.
• Use in patients with compromised immune systems who may not mount adequate vaccine response.
• Administration when the exposure risk is high and timely vaccine initiation is required.
• Provision of short‑term protection until active immunity develops.

• Human Rabies Immunoglobulin supplies exogenous anti‑rabies IgG antibodies that bind to the rabies virus glycoprotein. By forming immune complexes, the antibodies prevent viral attachment to neuronal receptors and block retrograde transport along peripheral nerves. This passive neutralization limits viral spread to the central nervous system, providing immediate protection while the recipient’s own immune system generates an active response after vaccination.

Human Rabies Immunoglobulin may be associated with local and systemic reactions; most are mild, transient, and resolve without intervention, while rare serious events have been reported in clinical use. Patients should be monitored after administration for any unexpected response.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever or chills.
• Headache or mild fatigue.
• Nausea or mild gastrointestinal discomfort.
• Mild muscle aches at the injection site.
• Transient dizziness or light‑headedness.

Serious

• Severe allergic reaction (anaphylaxis) with hives, difficulty breathing, or hypotension.
• Serum sickness–like illness presenting with fever, rash, and arthralgia.
• Neurologic symptoms such as seizures or encephalopathy (very rare).
• Severe local necrosis or ulceration at the injection site (extremely rare).

When using Human Rabies Immunoglobulin, clinicians should consider several precautionary measures to ensure safe administration and optimal protection.

• Verify that the patient has not previously received rabies immune globulin to avoid duplicate dosing.
• Assess for known hypersensitivity to human immunoglobulins or any component of the formulation.
• Use the product only for post‑exposure prophylaxis; it is not a substitute for the rabies vaccine schedule.
• Adjust the dose according to the recommended volume based on wound severity and patient body weight.
• Monitor the injection site and vital signs for at least 30 minutes after administration.
• Exercise caution in pregnant or lactating women; the risk–benefit profile should be evaluated.

Human Rabies Immunoglobulin can interact with other agents administered concurrently; awareness of potential interactions helps maintain the efficacy of the rabies prophylaxis regimen.

Avoid

• Simultaneous intramuscular injection of other vaccines at the same site, which may reduce the immune response to both products.
• Administration of blood products containing anti‑rabies antibodies that could cause an excess of immunoglobulin.

Use with caution

• Live attenuated vaccines given within 30 days, as passive antibodies may interfere with their effectiveness.
• Immunosuppressive therapy, which could diminish the overall protective effect of the passive antibodies.
• High‑dose intravenous immunoglobulin (IVIG) therapy, which may compete for Fc receptors and alter pharmacokinetics.